Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 20

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 20
---
 the foreseeable future. As discussed
in our financial statements, there exists substantial doubt regarding our ability to continue as a going concern.

Research and development
efforts are highly dependent on the amount of cash and cash equivalents on hand combined with our ability to raise additional capital
to support our future operations through one or more methods, including but not limited to, issuing additional equity or debt.

In addition, we may also
raise additional capital through additional equity offerings and licensing our research and/or future products in development. While we
will continue to explore these potential opportunities, there can be no assurances that we will be successful in raising sufficient capital
on terms acceptable to us, or at all, or that we will be successful in licensing our future products. Based on our current projections,
we believe we have insufficient cash on hand to meet our obligations as they become due based on current assumptions. The uncertainties
surrounding our future cash inflows have raised substantial doubt regarding our ability to continue as a going concern.

14

One of our current
projects is our 5-year cannabis genomic study being conducted by Sangre. In the event that we are unable to complete that study for any
reason, such as inability to complete our human clinical trials, or if those trials are not successful, then it could significantly impact
our business.

Although we have plans to
be a company with a multitude of business segments, one of our first forays into medical cannabis research is the 5-year cannabis genomic
study being conducted by Sangre. In the event that we are unable to complete the 5-year study for any reason, such as the inability to
complete our planned human clinical trials in phases 2 and 3 of the study, or if those trials are not successful, then it could significantly
impact our business.

Our research plan,
which is focused on the development and application of cannabis-derived compounds for the treatment of human disease, and includes our
5-year cannabis genomic study being conducted by Sangre, is dependent upon our ability to complete the necessary research and clinical
human trials.

Our research plan, which
is focused on the development and application of cannabis-derived compounds for the treatment of human disease, and includes our 5-year
cannabis genomic study being conducted by Sangre, is dependent upon our ability to complete the necessary research and clinical human
trials. In the event that we are unable to complete those research and/or human clinical trials, or if those trials are not successful,
then it could significantly, negatively impact all